Buying Cerebrolysin is not like buying a typical research peptide. It ships as a pre-mixed injectable solution at 215.2 mg/mL rather than a freeze-dried powder, it is priced and dosed by the millilitre, and because it is a mixture of low-molecular-weight peptides and free amino acids derived from porcine brain protein, the standard "98%+ HPLC purity" check does not apply to it. The research-market listing we track is a 10 mL vial priced at $119.99 (checked 1 October 2026), which works out to about $12 per mL.
That changes what a careful buyer evaluates: the stated concentration and fill volume, batch traceability, the testing lab, and sterility documentation matter more than a purity percentage. This guide covers how Cerebrolysin is priced, what a certificate of analysis can and cannot prove for a mixture, and how the published course volumes translate into vial counts. It pairs with our Cerebrolysin dosing guide and Cerebrolysin benefits article.
Research-context information only. Cerebrolysin is approved as a medicine in some countries but is not approved by the FDA; research-market solutions are sold for research purposes only and are not shown to be equivalent to the pharmaceutical product. Protocols, doses, and reactions reported below come from published clinical trials and self-reported community sources. This article reports what has been documented, not what should be done. Possession or use of an unapproved drug outside an authorized clinical trial may be restricted in your jurisdiction. Consult a licensed physician for personal medical decisions.
This is not a ranked vendor list — for live offers, see our Best Cerebrolysin Vendors page. This guide explains how any Cerebrolysin listing can be evaluated.
Understanding Cerebrolysin Pricing
Cerebrolysin is a biologic made by controlled enzymatic breakdown of purified pig-brain proteins, not a sequence built on a peptide synthesizer. That has two pricing consequences. First, it is a low-volume, specialty product — far fewer vendors list it than list BPC-157 or the GLP-1s, so there is little price competition. Second, it is sold as a liquid, so the meaningful unit is millilitres at a stated concentration, not milligrams of powder.
Current Market Pricing (2026)
| Format | Price (checked 1 Oct 2026) | Price per mL | With 10% partner code | Notes |
|---|---|---|---|---|
| 10 mL vial, 215.2 mg/mL | $119.99 | ~$12.00/mL | ~$10.80/mL | Research-market solution; COA posted by the vendor |
The vendor we currently track for Cerebrolysin is Mile High Compounds (affiliate link — we earn a commission on purchases through it), whose 10 mL listing was in stock when checked. The listing is labeled for research use only, not for human consumption. Code takes 10% off at their checkout. Prices change; the live figure is always on the Cerebrolysin vendor page.
The pattern is clear: with one common format and little competition, the levers are the partner discount and larger orders amortizing shipping — not hunting for a cheaper vial size.
Why Per-mg Comparisons Mislead
A 10 mL vial at 215.2 mg/mL contains about 2,152 mg of material, which makes the per-mg figure look tiny (roughly $0.06/mg). That number is not comparable to a single-peptide price per mg. Published descriptions of the pharmaceutical concentrate report roughly three-quarters free amino acids and one-quarter low-molecular-weight peptides, so most of those milligrams are not "active peptide" in the sense a retatrutide or BPC-157 milligram is. Compare Cerebrolysin listings per mL at the same stated concentration, and treat any listing that does not state a concentration as unpriceable.
What a Course Costs in Vials
Every published regimen is expressed as millilitres per day over a course, which is why total cost scales quickly. Published trial regimens and community accounts are shown only to illustrate how volume drives cost; the trial regimen was clinician-administered IV infusion and is not something research-market material is shown to replicate.
| Documented regimen | Total volume | 10 mL vials | Approx. cost at $119.99 |
|---|---|---|---|
| Self-reported community volumes (unverified source class) | ~50-100 mL total | 5-10 | — |
| Alzheimer's meta-analysis, 30 mL/day IV x 4 weeks (PMID 25832905) | ~840 mL | 84 | ~$10,000 |
These rows convert reported volumes to vial counts for cost scale only; this article does not describe a recommended or validated regimen. The community figures are self-reported and not trial-validated; the trial regimen was delivered by IV infusion under clinical supervision. The gap between the two rows is the single most important cost fact about Cerebrolysin: trial-scale volumes are roughly an order of magnitude larger than what community sources describe. For the full indication-by-indication breakdown, see the Cerebrolysin dosing guide.
How to Verify Cerebrolysin Quality
For a defined peptide, a COA answers two questions cleanly: is it the right molecule (mass spectrometry), and how pure is it (HPLC). Cerebrolysin breaks both. It has no single molecular weight to confirm and no single peak to measure purity against — a chromatogram of a peptide mixture is supposed to show many peaks. So the honest question is narrower: does the documentation prove what is in this specific vial, and that it is safe to be an injectable solution?
What a Buyer Can Verify
Content and concentration
- Stated concentration in mg/mL (the reference concentrate is 215.2 mg/mL) and the fill volume
- A total-content or protein/peptide-content result, not just a label claim
Traceability
- A batch or lot number that matches the label on the vial received
- A test date recent enough to belong to the batch being sold
- A named testing laboratory, not an unattributed in-house sheet
Injectable-solution safety (if reported)
- Sterility testing
- Bacterial endotoxin results
- Appearance: a clear solution without particulates or cloudiness
As an example of what a posted COA looks like, Mile High Compounds' listing references batch CBL-001-MH, tested by Vanguard Laboratory, reporting roughly 215 mg/mL across the 10 mL fill. That documents concentration, batch, and lab; whether sterility and endotoxin are also covered is the question a buyer would check on the COA itself.
What a COA Cannot Prove
- Equivalence to the pharmaceutical product. The clinical trials cited on this site used the standardized pharmaceutical preparation. A research-market solution with a matching concentration is not shown to have the same peptide composition, and no COA format can establish that.
- A "purity %." A single purity figure on a Cerebrolysin COA should be read with caution — it raises the question of what was measured, since there is no single target molecule.
- Biological activity. Concentration testing measures how much material is present, not whether it behaves like the material studied in trials.
How a COA Is Typically Checked
- A legitimate COA names Cerebrolysin and a specific batch/lot number, not a generic template.
- The lot number on the COA matches the vial received.
- The named laboratory exists and performs the tests listed.
- The test date fits the batch being sold.
- Reputable vendors supply the lot-specific COA on request; a vendor that cannot produce one is a signal.
Red Flags to Avoid
- No stated concentration, or a concentration that differs from the label
- A lyophilized powder sold under the Cerebrolysin name (that is a different preparation — see below)
- A single high "purity %" with no explanation of the method
- No batch number, or a COA lot that does not match the vial
- No sterility or endotoxin information for a product sold as a ready-to-inject solution
- Prices far below what other listings state for the same concentration and volume
